7th DIA Cardiac Safety Workshop in Japan

It will be a unique opportunity to learn of and discuss the current state and future directions of CV risk assessments and how to prepare for a new regulatory paradigm.

Back to Agenda

[Session 2] Non Clinical Proarrhythmic Risk Assessment

Session Chair(s)

Katsuyoshi Chiba, PhD

Senior Director and Head, Group III, Medicinal Safety Research Laboratories, R&D

Daiichi Sankyo Co., Ltd., Japan

Yasunari Kanda, PhD

Head of Division of Pharmacology

National Institute of Health Sciences, Japan

Speaker(s)

Keynote Lecture: Prediction and Quantification of Torsadogenic Potential Using Classical and New Assay Models

Atsushi Sugiyama, MD, PhD

Toho University Faculty of Medicine, Japan

Professor and Chairman, Department of Pharmacology

CiPA: Validation Efforts and Update

Gary Gintant, PhD

AbbVie Inc., United States

Research Fellow

JiCSA Update: Proarrhythmia Risk Assessment Using Human iPS Cell-derived Cardiomyocytes

Yasunari Kanda, PhD

National Institute of Health Sciences, Japan

Head of Division of Pharmacology

iSmart (investigation of in silico / in vitro model for Arrhythmogenic Risk Prediction) Update

Keiichi Asakura, PhD

Nippon Shinyaku Co., Ltd., Japan

Senior Scientist, Pharmacokinetics and Safety Assessment Department

Have an account?

7th DIA Cardiac Safety Workshop in Japan

[Session 2] Non Clinical Proarrhythmic Risk Assessment

Session Chair(s)

Katsuyoshi Chiba, PhD

Yasunari Kanda, PhD

Speaker(s)

Keynote Lecture: Prediction and Quantification of Torsadogenic Potential Using Classical and New Assay Models

CiPA: Validation Efforts and Update

JiCSA Update: Proarrhythmia Risk Assessment Using Human iPS Cell-derived Cardiomyocytes

iSmart (investigation of in silico / in vitro model for Arrhythmogenic Risk Prediction) Update

Be informed and stay engaged.